open access

Vol 12, No 2 (2016)
Review paper
Published online: 2016-08-04
Get Citation

Nivolumab — perspectives in cancer treatment

Hanna Koseła, Piotr Rutkowski
Oncol Clin Pract 2016;12(2):52-62.

open access

Vol 12, No 2 (2016)
REVIEW ARTICLES
Published online: 2016-08-04

Abstract

Blockade of the immune checkpoint PD-1 is a new and promising strategy for the treatment of advanced cancers. The introduction of nivolumab has improved prognosis in a large group of cancer patients. Currently, it is possible to obtain results of treatment that have not previously been observed in cancer immunotherapy. It seems that nivolumab has less treatment toxicity than many conventional chemo-therapeutics or ipilimumab. Nivolumab is currently registered in oncology patients with advanced melanoma, kidney cancer, and non-small cell lung cancer. In the near future the scope of registration of the drug will probably expand to other indications in malignant tumours. More details on the activity of the drug used in a variety of schemes and various types of cancer, as well as predictive factors of therapy, will be available after the announcement of further results of ongoing numerous clinical studies using nivolumab.

Abstract

Blockade of the immune checkpoint PD-1 is a new and promising strategy for the treatment of advanced cancers. The introduction of nivolumab has improved prognosis in a large group of cancer patients. Currently, it is possible to obtain results of treatment that have not previously been observed in cancer immunotherapy. It seems that nivolumab has less treatment toxicity than many conventional chemo-therapeutics or ipilimumab. Nivolumab is currently registered in oncology patients with advanced melanoma, kidney cancer, and non-small cell lung cancer. In the near future the scope of registration of the drug will probably expand to other indications in malignant tumours. More details on the activity of the drug used in a variety of schemes and various types of cancer, as well as predictive factors of therapy, will be available after the announcement of further results of ongoing numerous clinical studies using nivolumab.

Get Citation

Keywords

immunotherapy, PD-1 inhibitor, drug combinations, toxicity of immunotherapy

About this article
Title

Nivolumab — perspectives in cancer treatment

Journal

Oncology in Clinical Practice

Issue

Vol 12, No 2 (2016)

Article type

Review paper

Pages

52-62

Published online

2016-08-04

Bibliographic record

Oncol Clin Pract 2016;12(2):52-62.

Keywords

immunotherapy
PD-1 inhibitor
drug combinations
toxicity of immunotherapy

Authors

Hanna Koseła
Piotr Rutkowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl